Thang M. Le , Huyen N. Nguyen , Ngoc T. Vu , Phong Q. Le
{"title":"非对映异构体天然产物的合成和生物学评价:α-葡萄糖苷酶抑制的新型协同组合的发现","authors":"Thang M. Le , Huyen N. Nguyen , Ngoc T. Vu , Phong Q. Le","doi":"10.1016/j.bmcl.2025.130239","DOIUrl":null,"url":null,"abstract":"<div><div>Cabraleahydroxylactone (<strong>1a</strong>) and 3-epi-cabraleahydroxylactone (<strong>1b</strong>) are naturally diastereomers found in <em>Aglaia abbreviata</em>, known for their biological potential. While <strong>1b</strong> has been synthesized and studied as an anti-diabetic agent, the activity of <strong>1a</strong> remained unexplored. This study successfully enhanced <strong>1a</strong> in the reaction mixture through the reduction of cabralealactone (<strong>2</strong>), increasing its ratio from trace levels to 9.5:1 (<strong>1b</strong>:<strong>1a</strong>). Molecular docking revealed distinct binding interactions of these diastereomers with α-glucosidase allosteric sites, suggesting a drug synergy mechanism. Kinetic studies confirmed non-competitive inhibition by both compounds, with <strong>1a</strong> exhibiting superior binding affinity (lower Ki). Synergistic α-glucosidase inhibition was observed in specific <strong>1b</strong>:<strong>1a</strong> ratios (9:1, 8:2, 2:8, and 1:9). Furthermore, these combinations displayed reduced hemolytic toxicity compared to individual compounds. The findings highlight the <strong>1b</strong>:<strong>1a</strong> diastereomeric combination as a promising lead for anti-diabetic drug development, offering enhanced efficacy and safety through synergistic interactions.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"123 ","pages":"Article 130239"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and biological evaluation of diastereomeric natural products: Discovery of a novel synergistic combination for α-glucosidase inhibition\",\"authors\":\"Thang M. Le , Huyen N. Nguyen , Ngoc T. Vu , Phong Q. Le\",\"doi\":\"10.1016/j.bmcl.2025.130239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Cabraleahydroxylactone (<strong>1a</strong>) and 3-epi-cabraleahydroxylactone (<strong>1b</strong>) are naturally diastereomers found in <em>Aglaia abbreviata</em>, known for their biological potential. While <strong>1b</strong> has been synthesized and studied as an anti-diabetic agent, the activity of <strong>1a</strong> remained unexplored. This study successfully enhanced <strong>1a</strong> in the reaction mixture through the reduction of cabralealactone (<strong>2</strong>), increasing its ratio from trace levels to 9.5:1 (<strong>1b</strong>:<strong>1a</strong>). Molecular docking revealed distinct binding interactions of these diastereomers with α-glucosidase allosteric sites, suggesting a drug synergy mechanism. Kinetic studies confirmed non-competitive inhibition by both compounds, with <strong>1a</strong> exhibiting superior binding affinity (lower Ki). Synergistic α-glucosidase inhibition was observed in specific <strong>1b</strong>:<strong>1a</strong> ratios (9:1, 8:2, 2:8, and 1:9). Furthermore, these combinations displayed reduced hemolytic toxicity compared to individual compounds. The findings highlight the <strong>1b</strong>:<strong>1a</strong> diastereomeric combination as a promising lead for anti-diabetic drug development, offering enhanced efficacy and safety through synergistic interactions.</div></div>\",\"PeriodicalId\":256,\"journal\":{\"name\":\"Bioorganic & Medicinal Chemistry Letters\",\"volume\":\"123 \",\"pages\":\"Article 130239\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic & Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960894X25001489\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X25001489","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Synthesis and biological evaluation of diastereomeric natural products: Discovery of a novel synergistic combination for α-glucosidase inhibition
Cabraleahydroxylactone (1a) and 3-epi-cabraleahydroxylactone (1b) are naturally diastereomers found in Aglaia abbreviata, known for their biological potential. While 1b has been synthesized and studied as an anti-diabetic agent, the activity of 1a remained unexplored. This study successfully enhanced 1a in the reaction mixture through the reduction of cabralealactone (2), increasing its ratio from trace levels to 9.5:1 (1b:1a). Molecular docking revealed distinct binding interactions of these diastereomers with α-glucosidase allosteric sites, suggesting a drug synergy mechanism. Kinetic studies confirmed non-competitive inhibition by both compounds, with 1a exhibiting superior binding affinity (lower Ki). Synergistic α-glucosidase inhibition was observed in specific 1b:1a ratios (9:1, 8:2, 2:8, and 1:9). Furthermore, these combinations displayed reduced hemolytic toxicity compared to individual compounds. The findings highlight the 1b:1a diastereomeric combination as a promising lead for anti-diabetic drug development, offering enhanced efficacy and safety through synergistic interactions.
期刊介绍:
Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.